[{"id":"961c39f5-982d-49c6-8dfa-778598f18be0","acronym":"","url":"https://clinicaltrials.gov/study/NCT06093841","created_at":"2023-10-23T20:14:00.026Z","updated_at":"2025-02-25T15:28:23.588Z","phase":"Phase 2","brief_title":"Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL","source_id_and_acronym":"NCT06093841","lead_sponsor":"Shanghai Ming Ju Biotechnology Co., Ltd.","biomarkers":" BCL2","pipe":" | ","alterations":" MYC rearrangement • BCL2 rearrangement","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Carteyva (relmacabtagene autoleucel)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 11/03/2023","start_date":" 11/03/2023","primary_txt":" Primary completion: 01/21/2024","primary_completion_date":" 01/21/2024","study_txt":" Completion: 11/04/2029","study_completion_date":" 11/04/2029","last_update_posted":"2025-02-11"},{"id":"48501323-09cb-4f5b-a243-32ead55180fa","acronym":"","url":"https://clinicaltrials.gov/study/NCT05370547","created_at":"2022-05-11T15:55:57.619Z","updated_at":"2024-07-02T16:35:16.239Z","phase":"Phase 1/2","brief_title":"Chidamide Bridging for CAR-T Therapy","source_id_and_acronym":"NCT05370547","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" BCL2 • BCL6 • PMAIP1","pipe":" | ","alterations":" CD19 positive","tags":["BCL2 • BCL6 • PMAIP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Yescarta (axicabtagene ciloleucel) • Epidaza (chidamide) • fludarabine IV • Carteyva (relmacabtagene autoleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 05/25/2022","start_date":" 05/25/2022","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-03-06"},{"id":"14dbcfcb-018a-43c3-b986-6994fde4c7d8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05590221","created_at":"2022-10-21T13:55:57.327Z","updated_at":"2024-07-02T16:35:24.232Z","phase":"Phase 2","brief_title":"Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma","source_id_and_acronym":"NCT05590221","lead_sponsor":"Peking University Cancer Hospital \u0026 Institute","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Carteyva (relmacabtagene autoleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 01/03/2023","start_date":" 01/03/2023","primary_txt":" Primary completion: 02/10/2024","primary_completion_date":" 02/10/2024","study_txt":" Completion: 12/10/2024","study_completion_date":" 12/10/2024","last_update_posted":"2024-01-08"},{"id":"0b7184b4-3c84-4f15-b811-c4e7f66c51ac","acronym":"","url":"https://clinicaltrials.gov/study/NCT05259813","created_at":"2022-03-02T18:52:40.344Z","updated_at":"2024-07-02T16:35:28.216Z","phase":"Phase 1","brief_title":"Phase I Study of JWCAR029 in Subjects With R/R CLL/SLL","source_id_and_acronym":"NCT05259813","lead_sponsor":"Shanghai Ming Ju Biotechnology Co., Ltd.","biomarkers":" CD5","pipe":"","alterations":" ","tags":["CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Carteyva (relmacabtagene autoleucel)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 02/28/2022","start_date":" 02/28/2022","primary_txt":" Primary completion: 01/31/2023","primary_completion_date":" 01/31/2023","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2023-11-24"},{"id":"c48979e3-64ea-4771-a798-e9c4c7ebc86b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04718883","created_at":"2021-01-22T13:53:16.999Z","updated_at":"2024-07-02T16:35:28.166Z","phase":"Phase 2","brief_title":"CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma","source_id_and_acronym":"NCT04718883","lead_sponsor":"Shanghai Ming Ju Biotechnology Co., Ltd.","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Carteyva (relmacabtagene autoleucel)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 59","initiation":"Initiation: 01/13/2021","start_date":" 01/13/2021","primary_txt":" Primary completion: 10/25/2023","primary_completion_date":" 10/25/2023","study_txt":" Completion: 08/07/2028","study_completion_date":" 08/07/2028","last_update_posted":"2023-11-24"},{"id":"cfdb1366-06fc-4b61-a68f-72f0a73cac9b","acronym":"RELIANCE","url":"https://clinicaltrials.gov/study/NCT04089215","created_at":"2021-01-17T17:21:03.921Z","updated_at":"2024-07-02T16:35:28.185Z","phase":"Phase 2","brief_title":"CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma","source_id_and_acronym":"NCT04089215 - RELIANCE","lead_sponsor":"Shanghai Ming Ju Biotechnology Co., Ltd.","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Carteyva (relmacabtagene autoleucel)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 82","initiation":"Initiation: 06/11/2019","start_date":" 06/11/2019","primary_txt":" Primary completion: 09/10/2021","primary_completion_date":" 09/10/2021","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2023-11-24"},{"id":"bd6f624d-1157-469d-b72b-275cd9991f72","acronym":"","url":"https://clinicaltrials.gov/study/NCT04812691","created_at":"2021-03-24T16:10:45.905Z","updated_at":"2024-07-02T16:35:28.298Z","phase":"Phase 1","brief_title":"CD19-targeted CAR T Cells （JWCAR029） for Primary Refractory Diffuse Large B Cell Lymphoma","source_id_and_acronym":"NCT04812691","lead_sponsor":"Shanghai Ming Ju Biotechnology Co., Ltd.","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Carteyva (relmacabtagene autoleucel)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 07/10/2020","start_date":" 07/10/2020","primary_txt":" Primary completion: 06/30/2021","primary_completion_date":" 06/30/2021","study_txt":" Completion: 04/25/2023","study_completion_date":" 04/25/2023","last_update_posted":"2023-11-22"},{"id":"2a8a64fd-0b17-4de0-a226-684f15b31008","acronym":"","url":"https://clinicaltrials.gov/study/NCT05806580","created_at":"2023-08-01T17:09:57.895Z","updated_at":"2024-07-02T16:35:41.329Z","phase":"Phase 4","brief_title":"Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma","source_id_and_acronym":"NCT05806580","lead_sponsor":"Ruijin Hospital","biomarkers":" BCL2 • BCL6","pipe":"","alterations":" ","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Carteyva (relmacabtagene autoleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 05/01/2022","start_date":" 05/01/2022","primary_txt":" Primary completion: 05/31/2027","primary_completion_date":" 05/31/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2023-08-01"},{"id":"c9fbafad-6262-4580-8acd-59558662ff8d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05814848","created_at":"2023-04-18T15:04:19.195Z","updated_at":"2024-07-02T16:35:45.576Z","phase":"Phase 4","brief_title":"A Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma","source_id_and_acronym":"NCT05814848","lead_sponsor":"Changhai Hospital","biomarkers":" BCL2 • BCL6","pipe":"","alterations":" ","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Carteyva (relmacabtagene autoleucel)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 13","initiation":"Initiation: 06/20/2023","start_date":" 06/20/2023","primary_txt":" Primary completion: 03/31/2028","primary_completion_date":" 03/31/2028","study_txt":" Completion: 03/31/2028","study_completion_date":" 03/31/2028","last_update_posted":"2023-06-15"}]